Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Assay Kit / ADA/PK Assay Elisa Kit

Losatuxizumab ELISA Kit (KDB86902)

Sample type:Plasma, Serum
Sensitivity:0.156 μg/ml
Range:0.31-5 μg/mL
Overview

Catalog No.

KDB86902

Detection method

Colorimetric

Sample type

Plasma, Serum

Assay type

Quantitative

Range

0.31-5 μg/mL

Sensitivity

0.156 μg/ml

Precision

CV<20%

Recovery

80-120%

Shipping

2-8 ℃

Stability and Storage

The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.

Alternative Names

ABT-806, PR-1316749, CAS: 1801544-27-3

Background

Losatuxizumab is a biosimilar that targets EGFR. EGFR (Epidermal growth factor receptor, HER1, ErbB1) is encoded by the EGFR gene located on chromosome 7 in humans. EGFR belongs to the HER/ERbB family of proteins that includes three other receptor tyrosine kinases, ERbB2, ERbB3, ERbB4. EGFR is a transmembrane receptor and binding of its cognate ligands such as EGF (Epidermal Growth Factor) and TGF alpha (Transforming Growth Factor alpha) to the extracellular domain leads to EGFR dimerization followed by autophosphorylation of the tyrosine residues in the cytoplasmic domain. Phosphorylation of EGFR at certain residues is also mediated by Src-non-receptor kinase. EGFR activation signals multiple downstream signaling cascades such as the Ras - ERK, pi3-K - Akt, Jak - STAT and PKC pathways that help in growth and proliferation of cells. Phosphorylation of EGFR at Y1086 specifically allows binding of the adaptor protein GRB2, leading to activation of the MAPK pathway. Upon receptor activation and signaling, EGFR is endocytosed and targeted for degradation or recycling. Mutations in the EGFR gene are associated with lung cancer and multiple alternatively spliced transcript variants encode different protein isoforms of EGFR have been found. Increased production or activation of EGFR has been associated with poor prognosis in a variety of tumors. Moreover, EGFR overexpression is observed in tumors of the head and neck, brain, bladder, stomach, breast, lung, endometrium, cervix, vulva, ovary, esophagus, stomach and in squamous cell carcinoma.

Data Image
References
Datasheet

Document Download

Losatuxizumab ELISA Kit.pdf

 

$ 1128
Product specifications
96T 1128

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Losatuxizumab ELISA Kit [KDB86902]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2024 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only